DURHAM, N.C., June 21, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that its common stock has been approved for secondary listing on the SIX Swiss Exchange in addition to its listing on the NASDAQ Capital Market. Bank am Bellevue of Zurich is acting as the company's listing agent.
"Broadening awareness of our company and making trading in our stock more accessible to our existing and potential shareholder bases were important considerations when we decided to list on the SIX," said Company Chairman and CEO Chris J. Stern. "While this listing took place by way of introduction with no new capital raised at this point, I believe it offers us access to a larger capital market, particularly in Europe."
Trading on the SIX for Oxygen Biotherapeutics' common stock is expected to begin on June 29, 2010. An announcement will be made signaling initiation of trading on the day it begins.
About the Company
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte® that is being formulated for both intravenous and topical delivery. In April, the company launched its first cosmetic product, Dermacyte® Oxygen Concentrate. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing. More information is available at www.oxybiomed.com or www.buydermacyte.com.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for listing on the SIX Swiss Exchange, the expansion of development of the Oxycyte product line and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in initial trading on the SIX Swiss Exchange, delays in the new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current report on Form 8-K filed on May 4, 2010. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.